Therapeutic targeting of oncogenic transforming growth factor-β1 signaling by antisense oligonucleotides in oral squamous cell carcinoma

Kim,Seong-Gon; Song,Ji-Young

doi:10.3892/or.2012.1811

Therapeutic targeting of oncogenic transforming growth factor-β1 signaling by antisense oligonucleotides in oral squamous cell carcinoma

Authors:
- Seong-Gon Kim
- Ji-Young Song
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, College of Dentistry, Gangneung-Wonju National University, Gangneung 210-702, Republic of Korea
Published online on: May 10, 2012 https://doi.org/10.3892/or.2012.1811
Pages: 539-544

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The transforming growth factor-β1 (TGF-β1) signaling pathway is important in human oral squamous cell carcinoma (OSCC). Accordingly, the aims of this study were to evaluate the effect of antisense TGF-β1 oligonucleotides (ODNs) on OSCC in cell culture and in a xenograft model, as well as to evaluate any effects ODNs have on proliferating cell nuclear antigen (PCNA) and matrix metalloproteinase-2 (MMP-2) expression in the xenograft model. We performed real-time cell electronic sensing (RT-CES) to determine the effect of antisense TGF-β1 ODNs on SCC-9 cell growth. To examine the in vivo effect of antisense TGF-β1 ODN therapy, SCC-9 cells were grafted into nude mice. Antisense ODNs were injected into the mass daily. Tumor size, body weight and duration of survival were assessed daily. Specimens from the main mass were used for immunohistochemical staining to analyze PCNA and MMP-2 expression. In vitro treatment with antisense TGF-β1 ODNs decreased TGF-β1 expression and growth of SCC-9 cells. In the xenograft model, the antisense TGF-β1 ODN group exhibited a significantly decreased tumor growth rate compared to the control, which received Dulbecco's modified Eagle's medium (DMEM) (P=0.022). However, mean survival time and body weights were not significantly different between the groups (P>0.05). Immunohistochemistry showed that tumors from animals that received antisense TGF-β1 ODNs had significantly lower expression levels of PCNA and MMP-2 compared to tumors from animals in the DMEM group (P<0.05). In conclusion, antisense TGF-β1 ODN therapy significantly inhibits tumor growth compared to controls, however, there are no significant differences between groups with respect to changes in body weight.

View Figures

View References

1	Kim ES, Kies M and Herbst RS: Novel therapeutics for head and neck cancer. Curr Opin Oncol. 14:334–342. 2002. View Article : Google Scholar : PubMed/NCBI
2	Hong SD, Hong SP, Lee JI and Lim CY: Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol. 36:207–213. 2000. View Article : Google Scholar : PubMed/NCBI
3	Lionetti P, Pazzaglia A, Moriondo M, et al: Differing patterns of transforming growth factor-β expression in normal intestinal mucosa and in active celiac disease. J Pediatr Gastroenterol Nutr. 29:308–313. 1999.
4	Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G and Gress TM: TGF-β-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer. 93:204–211. 2001.
5	Sier CFM, Kubben FJGM, Ganesh S, et al: Tissue level of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer. 74:413–417. 1996. View Article : Google Scholar : PubMed/NCBI
6	Wakefield LM and Roberts AB: TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 12:22–29. 2002.
7	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
8	Kovasc EJ: Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol Today. 12:17–23. 1991. View Article : Google Scholar : PubMed/NCBI
9	Stetler-Stevenson WG, Aznavoorian S and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 9:541–573. 1993. View Article : Google Scholar : PubMed/NCBI
10	Nagase H and Woessner JF Jr: Matrix metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar
11	Kim SG, Kim MH, Chae CH, Jung YK and Choi JY: Downregulation of matrix metalloproteinases in hyperplastic dental follicles results in abnormal tooth eruption. BMB Rep. 41:322–327. 2008. View Article : Google Scholar : PubMed/NCBI
12	Kim JY, Rotaru H and Kim SG: The clinical significance of the expression of TGF-β1 and MMP-2 related to the regional lymph node metastasis in the oral squamous cell carcinoma. J Korean Oral Maxillofac Surg. 33:199–203. 2007.
13	Park YW, Kim SG, Choi JY and Lee SK: Recapitulating orthotopic tumor model through establishment of a parotid gland tumor with lung metastasis using HeLa cell injection into nude mice. Oncol Rep. 23:701–708. 2010.PubMed/NCBI
14	Carlsson G, Gullberg B and Hafström L: Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol. 105:20–23. 1983.PubMed/NCBI
15	Roberts AB and Sporn MB: The transforming growth factors. Peptide Growth Factors and their Receptors I. Sporn MB and Roberts AB: Springer; Berlin: pp. 419–472. 1990, View Article : Google Scholar
16	Prime SS, Matthews JB, Patel V, et al: TGF-β receptor regulation mediates the response to exogenous ligand but is independent of the degree of cellular differentiation in human oral keratinocytes. Int J Cancer. 56:406–412. 1994.
17	Aiping H: Drug resistance and gene amplification potential regulated by transforming growth factor β1 gene expression. Cancer Res. 55:1758–1762. 1995.PubMed/NCBI
18	Yingling JM, Blanchard KL and Sawyer JS: Development of TGF-β signaling inhibitors for cancer therapy. Nat Rev Drug Discov. 3:1011–1022. 2004.
19	Moore LD, Isayeva T, Siegal GP and Ponnazhagan S: Clin Cancer Res. 14:4961–4970. 2008. View Article : Google Scholar
20	Woolf TM, Melton DA and Jennings CGB: Specificity of an antisense oligonucleotides in vivo. Proc Natl Acad Sci USA. 89:7305–7309. 1992. View Article : Google Scholar : PubMed/NCBI
21	Thierry AR, Rahman A and Dritschilo A: Liposomal delivery as a new approach to transport antisense oligonucleotides. Gene Regulation: Biology of Antisense RNA and DNA. Erickson R and Izant JF: Raven Press Ltd; New York: pp. 147–161. 1992
22	Cheng K, Yang N and Mahato RI: TGF-β1 gene silencing for treating liver fibrosis. Mol Pharm. 6:772–779. 2009.
23	Wilkins-Port CE and Higgins PJ: Regulation of extracellular matrix remodeling following transforming growth factor-beta1/epidermal growth factor-stimulated epithelial-mesenchymal transition in human premalignant keratinocytes. Cells Tissues Organs. 185:116–122. 2007. View Article : Google Scholar
24	Dasgupta S, Bhattacharya-Chatterjee M, O’Malley BW Jr and Chatterjee SK: Tumor metastasis is an orthotopic murine model of head and neck cancer: possible role of TGF-beta 1 secreted by the tumor cells. J Cell Biochem. 97:1036–1051. 2006. View Article : Google Scholar : PubMed/NCBI
25	Sun L, Diamond ME, Ottaviano AJ, Joseph MJ, Ananthanarayan V and Munshi HG: Transforming growth factor-β1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through Snail expression. Mol Cancer Res. 6:10–20. 2008.
26	Munshi HG, Wu YI, Mukhopadhyay S, et al: Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta 1-induced pericellular collagenolysis. J Biol Chem. 279:39042–39050. 2004. View Article : Google Scholar